An increasingly important issue is whether certain ART regimens are expected to have drug interactions when used with certain hormonal contraceptive methods. In theory, an interaction could affect the efficacy of either medication, or cause side effects or toxicity. If contraceptive efficacy decreases, the chances of contraceptive failure, unintended pregnancy, and the accompanying consequences increase.
10 December 2014 | K4Health
Sexual behavior of teenage girls does not appear to be impacted by the human papilloma virus (HPV) vaccine, according to Queen's University, Canada researchers Drs. Leah Smith and Linda Lévesque.
09 December 2014 | Eurekalert
First of all I want to give a big thank you to everyone who supported me in writing this article. This has been an absolutely amazing experience! I appreciate every single one of you more than you could ever possibly imagine!
09 December 2014 | wearehiv.org
Carla Koppell, USAID’s chief strategy officer, discusses linkages between gender-based violence prevention and efforts to reduce the spread of HIV: "This week we mark World AIDS Day. Appropriately, it occurs during the Sixteen Days of Activism Against Gender-Based Violence. Why so appropriate? Because we know that gender-based violence (GBV) prevention and response are critical to effectively treating and reducing the spread of HIV. Though not always self-evident, the connection is clear."
09 December 2014 | USAID
Taking Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) until shortly after conception of a child appears safe.
03 December 2014 | POZ
Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."
26 November 2014 | Huffington Post
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
On the heels of news that gay men had very high levels of protection from HIV infection through intermittent pre-exposure prophylaxis (PrEP) timed around sexual activity, a mathematical model predicts that most women would need to stick with a daily dose of Truvada (tenofovir/emtricitabine) to prevent HIV infection from vaginal sex.
12 November 2014 | The Body Pro
University of Washington researchers have created a discreet, quick-dissolving tampon out of silk-line fibers to protect women from HIV. The researchers would ideally like to develop a tampon to protect against HIV, herpes, and pregnancy — an all-in-one shield against the risks of sex. This could prove especially useful in developing countries, where women may not have easy access to other kinds of birth control.
04 November 2014 | Healthline News
The case was brought by three HIV-positive women who were subjected to sterilisation without their informed consent in public hospitals. The High Court found in favour of the women and held that the practice of coerced sterilisation violated the women’s legal rights.
04 November 2014 | Southern Africa Litigation Centre (press release)